E. F. Smit

Repeatability of 18F-FDG Uptake Measurements in Tumors: A Metaanalysis

R. Boellaard, R. Boellaard, M. Boers, 2012, The Journal of Nuclear Medicine.

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

D. Planchard, P. Jänne, M. Ahn, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.